A new study reveals a slight drop in U.S. obesity rates, driven by weight loss drugs, lifestyle changes post-COVID, and ...

But it might also trigger feelings of nausea. Another theory is that GLP-1s (glucagon-like peptide-1 receptor agonists) — the ...

Tv Therapeutics Inc. (NASDAQ:VTVT – Get Free Report) was the target of a large decrease in short interest in November. As of November 30th, there was short interest totalling 22,500 shares, a decrease ...

Patients who have heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) and high body mass index ...

Some people are not taking weight-loss medications responsibly, the physician says, and don't realize their full implications ...

Semaglutide use in diabetes patients is linked to a higher risk of NAION, a rare eye condition. A Danish-Norwegian study ...

New research found that some anti-obesity medications such as Wegovy and Zepbound may prompt people to drink less. These ...

The mean body mass index (BMI) and the prevalence of obesity both dropped in 2023 for the first time in more than a decade.

GLP-1RA dispensing has increased from 2022 and 2023, whereas metabolic bariatric surgery has decreased among individuals with obesity.

GLP-1 receptor agonist use is associated with benefits in a number of different disease and may help treat patients with lupus nephritis.

Treatment with GLP-1RAs was associated with significant improvements in obstructive sleep apnea-related health outcomes.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce the risk for clinically important kidney and cardiovascular disease outcomes in individuals with type 2 diabetes.